BeOne Medicines AG (ONC)

NASDAQ: ONC · USD

$373

+6.70 (+1.8%)· Recorded snapshot

Market cap	42.4B
Revenue (ttm)	6.1B
Net income (ttm)	655.7M
EPS (ttm)	$5.59
Shares out	113.7M
P/E (trailing)	66.7x
P/E (forward)	45.5x
Volume	243,381
Beta	0.61

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 6.1B
Net income (ttm): 655.7M
EPS (ttm): $5.59
P/E (trailing): 66.7x
P/E (forward): 45.5x
Market cap: 42.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E45.5

P25 n/aP50 n/aP75 n/a

Trailing P/E66.7

P25 n/aP50 n/aP75 n/a

ROE14.7

P25 n/aP50 n/aP75 n/a

ROIC33.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ONC indicators

Market & fundamental data

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001651308
Company name	BeOne Medicines AG
Country	Switzerland
Country code	US
CUSIP number	07725L102
Earnings date	2026-11-05
Earnings time	bmo
Employees	12,000
Employees change	1,000
Employees growth	9.09%
Enterprise value	$39.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2010
Industry	Biotechnology
Is primary listing	No
Is SPAC	No
ISIN number	US07725L1026
Last 10-K release date	2026-02-26
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$42.4B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$372.76
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ONC
Website	https://beonemedicines.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	1.5%
EV/Earnings	59.95x
EV/EBIT	42.58x
EV/EBITDA	36.68x
EV/FCF	29.55x
EV/Sales	6.41x
FCF / EV yield	3.38%
FCF yield	3.14%
Forward EV/Sales	5.44x
Forward P/E	45.46x
Forward P/S	5.86x
Graham number	76.84076
Graham upside	-79.37%
P/(FCF - SBC) ratio	52.63x
P/(OCF - SBC) ratio	44.18x
P/B ratio	8x
P/E ratio	66.72x
P/FCF ratio	31.84x
P/OCF ratio	28.54x
P/S ratio	6.91x
Price / tangible book value	8.28x
Price/EBITDA ratio	39.53x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.06%
EBITDA margin	17.48%
Effective tax rate	24.46%
FCF margin	21.7%
Gross margin	88.89%
Operating margin	15.06%
Pretax margin	14.16%
Profit margin	10.7%
Profit per employee	$54,642
Profitable quarters	6
Profitable years	1
Revenue per employee	$510,747
ROA	7.46%
ROA (5Y)	-8.44%
ROCE	13.08%
ROE	14.66%
ROE (5Y)	-20.17%
ROIC	33.62%
SBC / revenue	8.57%
Tax / revenue	3.47%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	166.67%
EPS growth (QoQ)	6.67%
EPS growth quarters	1
EPS growth years	3
FCF growth	443.29%
FCF growth (Q)	98.09%
FCF growth (QoQ)	171.16%
Gross profit growth	39.65%
Gross profit growth (Q)	33.01%
Gross profit growth 3Y	34.26%
Net income growth (Q)	151.28%
Net income growth (QoQ)	4.24%
Net income growth quarters	7
Net income growth years	3
OCF growth	159.81%
OCF growth (Q)	75.58%
OCF growth (QoQ)	129.87%
Operating income growth (Q)	269.85%
Revenue growth	34.35%
Revenue growth (Q)	29.63%
Revenue growth (QoQ)	12.66%
Revenue growth 10Y	96.54%
Revenue growth 3Y	50.14%
Revenue growth 5Y	45.28%
Revenue growth quarters	17
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-153.9M
Depreciation and amortization	$148.5M
EBIT	$923.1M
EBITDA	$1.1B
EPS	$5.59
FCF per share	$11.70
Financing cash flow	$1.1B
Free cash flow	$1.3B
Free cash flow minus SBC	$804.9M
Gross profit	$5.4B
Income taxes	$212.4M
Investing cash flow	$-182.5M
Net borrowing	$108.4M
Net cash flow	$2.5B
Net income	$655.7M
Operating cash flow minus SBC	$958.7M
Operating income	$923.1M
Revenue	$6.1B
Stock-based compensation	$525.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.65
Book value per share	$45.78
Debt / EBITDA	1.86
Debt / equity	0.4
Debt / FCF	1.54
Interest coverage	7.97
Long-term assets	$2B
Long-term liabilities	$1.9B
Net cash (debt)	$3B
Net cash / market cap	7.2%
Net cash growth	76.18%
Net debt / EBITDA	-2.84
Net debt / equity	-0.59
Net debt / FCF	-2.29
Piotroski F-Score	7
Property, plant and equipment	$1.8B
Shareholders' equity	$5.2B
Tangible book value	$5.1B
Tangible book value per share	$45.24
Total assets	$9.2B
Total cash	$5.1B
Total debt	$2B
Total liabilities	$4B
WACC	7.45%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.79
Current assets	$7.2B
Current liabilities	$2.1B
Current ratio	3.4
Inventory turnover	1.1
Net working capital	$300.7M
Quick ratio	2.91
Working capital	$5.1B
Working capital turnover	1.7

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-8.01%
Dividend yield	0%
Shareholder yield	-8.01%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1,035.84%
10Y return CAGR	27.51%
10Y total return	1,035.84%
150-day SMA	$324.07
1D price change	1.83%
1M price change	3.28%
1M total return	3.28%
1W price change	-3.08%
1W total return	-3.08%
1Y price change	18.15%
1Y return CAGR	18.16%
1Y total return	18.15%
20-day SMA	$365.73
200-day SMA	$324.69
3M price change	14.35%
3M total return	14.35%
3Y price change	118.64%
3Y return CAGR	29.78%
3Y total return	118.64%
50-day SMA	$363.21
50-day SMA vs 200-day SMA	50over200
52-week high	$388.66
52-week high date	2026-10-21
52-week low	$253.95
52-week low date	2026-06-11
5Y price change	1.47%
5Y return CAGR	0.29%
5Y total return	1.47%
6M price change	24.68%
6M total return	24.68%
All-time high	$426.56
All-time high date	2021-09-17
All-time low	$22.51
All-time low date	2016-02-11
Average true range (ATR)	$10.99
Average volume	376.6K
Beta (1Y)	0.85
Beta (2Y)	0.75
Beta (5Y)	0.61
Change from 52-week high	-4.09%
Change from 52-week low	46.79%
Change from all-time high	-12.63%
Change from all-time low	1,555.58%
Change from open	1.6%
Day's gap	0.22%
Dollar volume	$90.7M
High price	$375.18
Low price	$366.88
Monthly RSI	65.22
Open price	$366.88
Position in 52-week range	70.84%
Premarket change	-0.29%
Premarket close	$366.06
Premarket price	$365.00
Previous close	$366.06
Price vs 150-day SMA	15%
Price vs 20-day SMA	1.9%
Price vs 200-day SMA	14.78%
Price vs 50-day SMA	2.6%
Relative volume	0.65
RSI	54.56
Sharpe ratio	0.54
Sharpe ratio (3Y)	0.73
Sharpe ratio (5Y)	0.2
Sortino ratio	1
Sortino ratio (3Y)	1.25
Sortino ratio (5Y)	0.4
Volume	243.4K
Weekly RSI	60.95
YTD price change	22.67%
YTD total return	22.67%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	81M
Float percentage	71.2%
Shares change (QoQ)	0.02%
Shares change (YoY)	8.01%
Shares held by insiders	4.1%
Shares held by institutions	53.53%
Shares outstanding	113.7M
Short % of shares	2.39%
Short ratio	5 days

Deeper analysis on ONC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ONC report

Is a complete ONC research report available?

No complete published report is available for BeOne Medicines AG (ONC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BeOne Medicines AG (ONC)

Price

Financial snapshot

Fair-value bridge

Latest news · ONC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ONC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ONC

Frequently asked questions